Biocon Enters Transformative Phase as Global Biosimilars Leader with Unique Positioning

Biocon is a global biosimilars leader due to regulatory shifts in the US, strategic partnerships, and a robust insulin and GLP-1 portfolio. The company's acquisition of Viatris' biosimilars business has strengthened its position as one of the top five biosimilars companies globally. The USFDA's draft guidelines, which propose to waive off phase-III clinical trials for certain biosimilars, presents a significant opportunity for Biocon, allowing it to reduce R&D costs and accelerate growth.